Mestilbol

Mestilbol
Clinical data
Trade names	Monomestro, Monomestrol
Other names	Monomethylstilbestrol; Diethylstilbestrol monomethyl ether
Drug class	Nonsteroidal estrogen; Estrogen ether
Identifiers
	IUPAC name 4-[(E)-4-(4-methoxyphenyl)hex-3-en-3-yl]phenol;
CAS Number	18839-90-2;
PubChem CID	3032340;
ChemSpider	2297337;
UNII	N44U12UW5N;
ChEBI	CHEBI:34702;
CompTox Dashboard (EPA)	DTXSID90860231 DTXSID7022469, DTXSID90860231 ;
Chemical and physical data
Formula	C19H22O2
Molar mass	282.383 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=C(CC)C1=CC=C(C=C1)OC)C2=CC=C(C=C2)O;
	InChI InChI=1S/C19H22O2/c1-4-18(14-6-10-16(20)11-7-14)19(5-2)15-8-12-17(21-3)13-9-15/h6-13,20H,4-5H2,1-3H3/b19-18+; Key:CKMDPZMWUZDKAI-VHEBQXMUSA-N;

Mestilbol (brand name Monomestro or Monomestrol), also known as diethylstilbestrol monomethyl ether, is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol. It was developed by Wallace & Tiernan Company, patented in 1940, and introduced for medical use in the 1940s, but is now no longer marketed. Mestilbol was available both as oral tablets and in oil for intramuscular injection. The drug is gradually demethylated in the body into diethylstilbestrol and hence is a prodrug of diethylstilbestrol. Mestilbol is a highly active estrogen, although somewhat less so than diethylstilbestrol, but is longer-lasting in comparison.